{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:43:56Z","timestamp":1758818636521},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s00415-006-5004-0","type":"journal-article","created":{"date-parts":[[2006,9,24]],"date-time":"2006-09-24T19:40:15Z","timestamp":1159126815000},"page":"v25-v32","source":"Crossref","is-referenced-by-count":11,"title":["Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects"],"prefix":"10.1007","volume":"253","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"5004_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"Akiyama","year":"2000","unstructured":"Akiyama H, Barger S, Barnum S et al. (2000) Inflammation and Alzheimer\u2019s disease. Neurobiol Aging 21:383\u2013421","journal-title":"Neurobiol Aging"},{"key":"5004_CR2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/WNL.44.9.1652","volume":"44","author":"Amato","year":"1994","unstructured":"Amato AA, Cornman EW, Kissel JT (1994) Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology 44:1652\u20131654","journal-title":"Neurology"},{"key":"5004_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/clim.1999.4823","volume":"94","author":"Amemiya","year":"2000","unstructured":"Amemiya K, Semino-Mora C, Granger RP, Dalakas MC (2000) Downregulation of TGF-\u03b21 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 94:99\u2013104","journal-title":"Clin Immunol"},{"key":"5004_CR4","first-page":"66","volume":"24","author":"Askanas","year":"2006","unstructured":"Askanas V, Dalakas MC, Engel WK (2006) Inclusion-body myositis: clinical and pathologic aspects, and basic research potentially relevant to treatment. Neurology 24(Suppl 1):66","journal-title":"Neurology"},{"key":"5004_CR5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/art.10363","volume":"46","author":"Blank","year":"2002","unstructured":"Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46:1689\u20131690","journal-title":"Arthritis Rheum"},{"key":"5004_CR6","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/jnnp.62.4.426","volume":"62","author":"Barker","year":"1997","unstructured":"Barker RAMC (1997) Successful treatment of stiff-man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 62:426","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5004_CR7","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM et al. (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993\u20132000","journal-title":"N Engl J Med"},{"key":"5004_CR8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1749-6632.1995.tb27543.x","volume":"753","author":"Dalakas","year":"1995","unstructured":"Dalakas MC (1995) Pathogenetic mechanisms of postpolio syndrome: Morphological, electrophysiological, virological and immunopathological correlations. Ann NY Acad Sci 753:167\u2013185","journal-title":"Ann NY Acad Sci"},{"key":"5004_CR9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/archneur.55.12.1509","volume":"55","author":"Dalakas","year":"1998","unstructured":"Dalakas MC (1998) Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 55:1509\u20131512","journal-title":"Arch Neurol"},{"key":"5004_CR10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7326\/0003-4819-131-7-199910050-00008","volume":"131","author":"Dalakas","year":"1999","unstructured":"Dalakas MC (1999) Autoantibodies and immunopathogenesis of the stiff-person syndrome. In: Levy LM (moderator) The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 131:522\u2013530","journal-title":"Ann Intern Med"},{"key":"5004_CR11","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/00019052-199908000-00006","volume":"12","author":"Dalakas","year":"1999","unstructured":"Dalakas MC (1999) Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opinion in Neurology 12:403\u2013409","journal-title":"Curr Opinion in Neurology"},{"key":"5004_CR12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.55.10.1531","volume":"55","author":"Dalakas","year":"2000","unstructured":"Dalakas MC, Fujii M, Li M, McElroy B (2000) The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55:1531\u20131535","journal-title":"Neurology"},{"key":"5004_CR13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","volume":"57","author":"Dalakas","year":"2001","unstructured":"Dalakas MC, Li M, Fujii M, Jacobowitz DM (2001) Stiff-person syndrome: quantification, specificity and intrathecal synthesis of GAD65 antibodies. Neurology 57:780\u2013785","journal-title":"Neurology"},{"key":"5004_CR14","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","volume":"345","author":"Dalakas","year":"2001","unstructured":"Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B (2001) High-dose intravenous immunoglobulin for stiffperson syndrome. N Engl J of Med 345:1870\u20131876","journal-title":"N Engl J of Med"},{"key":"5004_CR15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","volume":"56","author":"Dalakas","year":"2001","unstructured":"Dalakas MC, Koffman BM, Fujii M, Spector S, Sivakumar K, Cupler E (2001) A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 56:323\u2013327","journal-title":"Neurology"},{"key":"5004_CR16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-510X(02)00314-3","volume":"205","author":"Dalakas","year":"2002","unstructured":"Dalakas MC (2002) Proinflammatory cytokines and motor neuron dysfunction: is there a connection in post-polio syndrome? J Neurol Sci 205:5\u20138","journal-title":"J Neurol Sci"},{"key":"5004_CR17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"Dalakas","year":"2003","unstructured":"Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971\u2013982","journal-title":"Lancet"},{"key":"5004_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","volume":"102","author":"Dalakas","year":"2004","unstructured":"Dalakas MC (2004) The use of intravenous immunoglobulin in the treatment of autoimmune neurological disorders: evidence-based indications and safety profile. Pharmacol Therapeutics 102:177\u2013193","journal-title":"Pharmacol Therapeutics"},{"key":"5004_CR19","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.291.19.2367","volume":"291","author":"Dalakas","year":"2004","unstructured":"Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367\u20132375","journal-title":"JAMA"},{"key":"5004_CR20","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/brain\/awh343","volume":"127","author":"Dalakas","year":"2004","unstructured":"Dalakas MC (2004) Inhibiting leucocyte recruitment to the brain by IVIg. Is it relevant to the treatment of demyelinating CNS disorders? (Editorial) Brain 127:2569\u20132571","journal-title":"Brain"},{"key":"5004_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00415-005-1105-4","volume":"252","author":"Dalakas","year":"2005","unstructured":"Dalakas MC (2005) The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 252(S):19\u201325","journal-title":"J Neurol"},{"key":"5004_CR22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/01.wnl.0000192129.65677.87","volume":"66","author":"Dalakas","year":"2006","unstructured":"Dalakas MC (2006) Inflammatory, immune and viral aspects of inclusion body myositis. Neurology 66(Suppl):533\u2013538","journal-title":"Neurology"},{"key":"5004_CR23","first-page":"219","volume":"2","author":"Dalakas","year":"2006","unstructured":"Dalakas MC (2006) Signaling pathways and immunobiology of inflammatory myopathies. Nature Clinic Practice 2:219\u2013227","journal-title":"Nature Clinic Practice"},{"key":"5004_CR24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/ana.20339","volume":"56","author":"Dauvilliers","year":"2004","unstructured":"Dauvilliers Y, Carlander B, Rivier F, Touchon J, Tafti M (2004) Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 56:905\u2013908","journal-title":"Ann Neurol"},{"key":"5004_CR25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4049\/jimmunol.156.2.818","volume":"156","author":"Daw","year":"1996","unstructured":"Daw K, Ujihara N, Atkinson M, Powers AC (1996) Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 156:818\u2013825","journal-title":"J Immunol"},{"key":"5004_CR26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.410440209","volume":"44","author":"Dinkel","year":"1998","unstructured":"Dinkel K MH, Jury KM et al. (1998) Inhibition of gama-aminoutric acid synthesis by glutamic acid decarboxylase autoantibodies in Stiff-Man syndrome. Ann Neurol 44:194\u2013201","journal-title":"Ann Neurol"},{"key":"5004_CR27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.10253","volume":"52","author":"Dodel","year":"2002","unstructured":"Dodel R, Hampel H, Depboylu C et al. (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer\u2019s disease. Ann Neurol 52:253\u2013256","journal-title":"Ann Neurol"},{"key":"5004_CR28","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1136\/jnnp.2003.033399","volume":"75","author":"Dodel","year":"2004","unstructured":"Dodel RC, Du Y, Depboylu C et al. (2004) Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry 75:1472\u20131474","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"5004_CR29","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/brain\/awg191","volume":"126","author":"Du","year":"2003","unstructured":"Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M (2003) Human anti-beta-amyloid antibodies block betaamyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 126:1935\u20131939","journal-title":"Brain"},{"key":"5004_CR30","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm0296-148","volume":"2","author":"Ellis","year":"1996","unstructured":"Ellis MT, Atkinson AM (1996) The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nature Medicine 2:148\u2013153","journal-title":"Nature Medicine"},{"key":"5004_CR31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1046\/j.1526-4637.2002.02018.x","volume":"3","author":"Goebel","year":"2002","unstructured":"Goebel A, Netal S, Schedel R, Sprotte G (2002) Human pooled immunoglobulin in the treatment of chronic pain syndromes. Pain Med 3:119\u2013127","journal-title":"Pain Med"},{"key":"5004_CR32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jneuroim.2005.01.018","volume":"162","author":"Goebel","year":"2005","unstructured":"Goebel A Goebel A, Vogel H et al. (2005) Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome. J Neuroimmunol 162:184\u2013189","journal-title":"J Neuroimmunol"},{"key":"5004_CR33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ana.20400","volume":"57","author":"Goebel","year":"2005","unstructured":"Goebel A, Stock M, Deacon R, Sprotte G,Vincent A (2005) Intravenous immunoglobulin response and evidence for pathogenic antibodies in a case of complex regional pain syndrome 1. Ann Neurol 57:463\u2013464","journal-title":"Ann Neurol"},{"key":"5004_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-510X(02)00316-7","volume":"5","author":"Gonzalez","year":"2002","unstructured":"Gonzalez H, Khademi M, Andersson M, Wallstrom E, Borg K, Olsson T (2002) Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 5:9\u201313","journal-title":"J Neurol Sci"},{"key":"5004_CR35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jneuroim.2004.01.010","volume":"150","author":"Gonzalez","year":"2004","unstructured":"Gonzalez H, Khademi M, Andersson M et al. (2004) Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production. J Neuroimmunol 150:139\u2013144","journal-title":"J Neuroimmunol"},{"key":"5004_CR36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(06)70447-1","volume":"5","author":"Gonzales","year":"2006","unstructured":"Gonzales H et al. (2006) Intravenous immunoglobulin for the post-polio syndrome; a randomized controlled trial. Lancet Neurology 5:493\u2013500","journal-title":"Lancet Neurology"},{"key":"5004_CR37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/archneur.58.2.225","volume":"58","author":"Honnorat","year":"2001","unstructured":"Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C et al. (2001) Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58:225\u2013230","journal-title":"Arch Neurol"},{"key":"5004_CR38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2003.11.012","volume":"81","author":"Huizing","year":"2004","unstructured":"Huizing M, Rakocevic G, Sparks SE, Mamali I, Goldfarb L, Krasnewich D, Gahl WA, Dalakas MC (2004) Hypoglycosylation of a-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metabolism 81:196\u2013202","journal-title":"Mol Genet Metabolism"},{"key":"5004_CR39","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1093\/brain\/awh297","volume":"127","author":"Lapointe","year":"2004","unstructured":"Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P (2004) IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 127:2649\u20132656","journal-title":"Brain"},{"key":"5004_CR40","first-page":"970","volume":"62","author":"Levy","year":"2005","unstructured":"Levy LM, Levy-Reis I, Fujii M, Dalakas MC (2005) Brain g-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 62:970\u2013974","journal-title":"Arch Neurol"},{"key":"5004_CR41","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00936885","volume":"242","author":"Meinck","year":"1995","unstructured":"Meinck HM, Ricker K, Hulser PJ, Solimena M (1995) Stiff man syndrome: neurophysiological findings in eight patients. J Neurol 242:134\u2013142","journal-title":"J Neurol"},{"key":"5004_CR42","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1212\/01.WNL.0000145661.01675.A8","volume":"63","author":"Murinson","year":"2004","unstructured":"Murinson BB, Butler M, Marfurt K, Gleason S, De Camilli P et al. (2004) Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology 63:2146\u20132148","journal-title":"Neurology"},{"key":"5004_CR43","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1212\/01.WNL.0000145836.72059.3B","volume":"63","author":"Pearce","year":"2004","unstructured":"Pearce DA, Atkinson M, Tagle DA (2004) Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 63:2001\u20132005","journal-title":"Neurology"},{"key":"5004_CR44","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.55.1.46","volume":"55","author":"Peltola","year":"2000","unstructured":"Peltola J, Kulmala P, Isojarvi J, Saiz A, Latvala K et al. (2000) Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 55:46\u201350","journal-title":"Neurology"},{"key":"5004_CR45","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.4049\/jimmunol.175.11.7755","volume":"75","author":"Raju","year":"2005","unstructured":"Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, Dalakas MC, Ortqvist E, Hampe CS (2005) Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 75:7755\u20137762","journal-title":"J Immunol"},{"key":"5004_CR46","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"Raju","year":"2005","unstructured":"Raju R, Dalakas MC (2005) Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biologic validation of clinical relevant genes. Brain 128:1887\u20131896","journal-title":"Brain"},{"key":"5004_CR47","doi-asserted-by":"crossref","unstructured":"Rakocevic G, Raju R, Semino-Mora, Dalakas MC (2006) Stiff Person Syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology (In press)","DOI":"10.1212\/01.wnl.0000237558.83349.d0"},{"key":"5004_CR48","first-page":"63","volume":"56","author":"Schmidt","year":"2004","unstructured":"Schmidt J, Voss JG, Raju R, Dalakas MC (2004) Effect of immunotherapy on expression of cytokines and chemokines in relation to beta-amyloid and ubiquitin in the muscle of patients with sporadic inclusion body myositis. Ann Neurol 56:63","journal-title":"Ann Neurol"},{"key":"5004_CR49","first-page":"A331","volume":"64","author":"Schmidt","year":"2005","unstructured":"Schmidt J et al. (2005) Distinct interplay between inflammatory and degeneration-associated molecules in sporadic IBM. Neurology 64(Suppl 1):A331\u2013A332","journal-title":"Neurology"},{"key":"5004_CR50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Int Med 121:259\u2013262","journal-title":"Ann Int Med"},{"key":"5004_CR51","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJM199005313222202","volume":"322","author":"Solimena","year":"1990","unstructured":"Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P (1990) Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 322:1555\u20131560","journal-title":"N Engl J Med"},{"key":"5004_CR52","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1212\/01.WNL.0000039780.13681.AD","volume":"59","author":"Vasconcelos","year":"2002","unstructured":"Vasconcelos OM, Raju R, Dalakas MC (2002) GNE mutations in an American family with quadriceps-sparing IBM. Neurology 59:1776\u20131780","journal-title":"Neurology"},{"key":"5004_CR53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11940-003-0024-x","volume":"5","author":"Vasconcelos","year":"2003","unstructured":"Vasconcelos OM, Dalakas MC (2003) Therapies for stiff person syndrome. Current Treatment Options in Neurology 5:79\u201390","journal-title":"Current Treatment Options in Neurology"},{"key":"5004_CR54","doi-asserted-by":"crossref","first-page":"7270","DOI":"10.1158\/1078-0432.CCR-04-0735","volume":"10","author":"Vernino","year":"2004","unstructured":"Vernino S, Lennon VA (2004) Autoantibody profiles and neurological correlations of Thymoma. Clin Cancer Res 10:7270\u20137275","journal-title":"Clin Cancer Res"},{"key":"5004_CR55","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1056\/NEJM200104193441612","volume":"344","author":"Weinberger","year":"2001","unstructured":"Weinberger DR (2001) Anxiety at the frontier of molecular medicine. N Engl J Med 344:1247\u20131249","journal-title":"N Engl J Med"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-5004-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-006-5004-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-006-5004-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T23:25:18Z","timestamp":1683588318000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-006-5004-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":55,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["5004"],"URL":"https:\/\/doi.org\/10.1007\/s00415-006-5004-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}